AUTHOR=Chang Kai-Ting , Kuo Hsuan-Fu , Chang Yu-Han , Wang Yu-Tsang , Yang Lii-Jia , Niu Sheng-Wen , Kuo I-Ching , Chen Yumay , Wen Zhi-Hong , Hung Chi-Chih , Chang Jer-Ming , Lin Hugo Y.-H 

TITLE=Association between the risk of heart failure hospitalization and end-stage renal disease with digoxin usage in patients with cardiorenal syndrome: A population-based study

JOURNAL=Frontiers in Public Health

VOLUME=Volume 10 - 2022

YEAR=2023

URL=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2022.1074017

DOI=10.3389/fpubh.2022.1074017

ISSN=2296-2565

ABSTRACT=<sec><title>Background</title><p>The management of the coexistence of heart disease and kidney disease is increasingly challenging for clinicians. Chronic kidney disease (CKD) is not only a prevalent comorbidity of patients with heart failure but has also been identified as a noteworthy risk factor for all-cause mortality and poor clinical outcomes. Digoxin is one of the commonest treatments for heart disease. There are few trials investigating the role of digoxin in patients with cardiorenal syndrome (CRS). This study aims to examine the association between digoxin usage and clinical outcomes in patients with CRS in a nationwide cohort.</p></sec><sec><title>Method</title><p>We conducted a population-based study that included 705 digoxin users with CRS; each patient was age, sex, comorbidities, and medications matched with three non-users who were randomly selected from the CRS population. Cox proportional hazards regression analysis was conducted to estimate the effects of digoxin on the incidence of all-cause mortality, congestive heart failure (CHF) hospitalization, coronary artery disease (CAD) hospitalization, and end-stage renal disease (ESRD).</p></sec><sec><title>Results</title><p>The all-cause mortality rate was significantly higher in digoxin users than in non-users (adjusted hazard ratio [aHR] = 1.26; 95% confidence interval [CI] = 1.09–1.46, <italic>p</italic> = <italic>0.002</italic>). In a subgroup analysis, there was significantly high mortality in the <italic>0.26–0.75</italic> defined daily dose (DDD) subgroup of digoxin users (aHR = 1.49; 95% CI = 1.23–1.82, <italic>p</italic>&lt;<italic>0.001</italic>). Thus, the <italic>p for trend</italic> was <italic>0.013</italic>. With digoxin prescription, the CHF hospitalization was significantly higher [subdistribution HR (sHR) = 1.17; 95% CI = 1.05–1.30, <italic>p</italic> = <italic>0.004</italic>], especially in the &gt;<italic>0.75 DDD</italic> subgroup (sHR = 1.19; 95% CI = 1.01–1.41, <italic>p</italic> = <italic>0.046; p for trend</italic> = <italic>0.006</italic>). The digoxin usage lowered the coronary artery disease (CAD) hospitalization in the &gt; <italic>0.75 DDD</italic> subgroup (sHR = 0.79; 95% CI = 0.63–0.99, <italic>p</italic> = <italic>0.048</italic>). In renal function progression, more patients with CRS entered ESRD with digoxin usage (sHR = 1.34; 95% CI = 1.16–1.54, <italic>p</italic>&lt;<italic>0.001</italic>). There was a significantly greater incidence of ESRD in the &lt; <italic>0.26 DDD</italic> and <italic>0.26</italic>–<italic>0.75 DDD</italic> subgroups of digoxin users (sHR = 1.32; 95% CI = 1.06–1.66, <italic>p</italic> = <italic>0.015</italic>; sHR = 1.44; 95% CI = 1.18–1.75; <italic>p for trend</italic>&lt;<italic>0.001</italic>).</p></sec><sec><title>Conclusion</title><p>Digoxin should be prescribed with caution to patients with CRS.</p></sec>